Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Protein shake could unlock better kidney tests

NCT ID NCT07368712

Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study is testing how reliable a kidney function test called renal functional reserve is. Researchers will give healthy people and those with kidney problems a protein shake, then take blood and urine samples to see how well their kidneys respond. The goal is to see if this test can be used in future studies to better monitor kidney health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more accurate test for measuring kidney function, helping doctors better monitor and manage chronic kidney disease.
What could go wrong
This is an early observational study with only 50 participants, so results may not apply to everyone. The test may not prove reliable enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 18 to 75 years of age inclusive, at the time of signing the ICF. * Stable medical condition defined as no new drug or other treatment prescribed for a chronic condition within 60 days prior to Study Day 1. * Body weight between 50 and 100 kg. * Female Participants: A participant is eligible to participate if not pregnant or breastfeeding. If a urine test cannot be confirmed as negative at screening (e.g., an ambiguous result), the participant must be excluded from participation. Exclusion Criteria: * Recent surgical intervention within 60 days prior to Study Day 1. * New clinical diagnosis established within 60 days prior to Study Day 1. * New drug prescription within 60 days prior to Study Day 1. * Relevant change in severity of any medical condition within 60 days prior to Study Day 1, e.g. disease flare. * Known congenital amino acid metabolism disorders. * Severe hypersensitivity to milk products. * Known liver cirrhosis. * Regular use of non-steroidal anti-inflammatory drugs (NSAIDs). * Impaired kidney function with eGFR \<30 mL/min/1.73m2

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury, renal insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury, renal insufficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bayer AG - Occupational Health Services

    RECRUITING

    Berlin, 13353, Germany